CTLA4 and melanoma: 2.1. Lymphocyte T Populations and Outcomes of Melanoma Patients Treated with Anti-PD-1 or Anti-CTLA-4 Monotherapy and Anti-PD-1 Plus Anti-CTLA-4 Combination